drugset
drugset / Trial / NCT05306275

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

NCT05306275 ↗

Phase 1 Completed 132 enrolled CSL Behring
RandomizedParallel-groupOpen-labelOther

Summary

This is an open-label, parallel-group, phase 1, single center study to assess the relative bioavailability of CSL312 administered subcutaneously via a prefilled syringe assembled to an autoinjector compared to a prefilled syringe assembled to a needle safety device in healthy, adult subjects.

Timeline

Start
2022-04-04
Primary completion
2022-09-27
Completion
2022-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject CSL312 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.